184 related articles for article (PubMed ID: 31835700)
1. A Hierarchical Machine Learning Model to Discover Gleason Grade-Specific Biomarkers in Prostate Cancer.
Hamzeh O; Alkhateeb A; Zheng JZ; Kandalam S; Leung C; Atikukke G; Cavallo-Medved D; Palanisamy N; Rueda L
Diagnostics (Basel); 2019 Dec; 9(4):. PubMed ID: 31835700
[TBL] [Abstract][Full Text] [Related]
2. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
Johnston WL; Catton CN; Swallow CJ
BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
[TBL] [Abstract][Full Text] [Related]
3. PRADclass: Hybrid Gleason Grade-Informed Computational Strategy Identifies Consensus Biomarker Features Predictive of Aggressive Prostate Adenocarcinoma.
Balraj AS; Muthamilselvan S; Raja R; Palaniappan A
Technol Cancer Res Treat; 2024; 23():15330338231222389. PubMed ID: 38226611
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Clinical Proof-of-concept of a Novel Platform Utilizing Biopsy-derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4).
Albala D; Manak MS; Varsanik JS; Rashid HH; Mouraviev V; Zappala SM; Ette E; Kella N; Rieger-Christ KM; Sant GR; Chander AC
Urology; 2019 Feb; 124():198-206. PubMed ID: 30312670
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
7. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
Jędroszka D; Orzechowska M; Hamouz R; Górniak K; Bednarek AK
PLoS One; 2017; 12(12):e0188842. PubMed ID: 29206234
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
Shukla S; Zhang X; Niknafs YS; Xiao L; Mehra R; Cieślik M; Ross A; Schaeffer E; Malik B; Guo S; Freier SM; Bui HH; Siddiqui J; Jing X; Cao X; Dhanasekaran SM; Feng FY; Chinnaiyan AM; Malik R
Neoplasia; 2016 Aug; 18(8):489-99. PubMed ID: 27566105
[TBL] [Abstract][Full Text] [Related]
9. Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness.
Hectors SJ; Cherny M; Yadav KK; Beksaç AT; Thulasidass H; Lewis S; Davicioni E; Wang P; Tewari AK; Taouli B
J Urol; 2019 Sep; 202(3):498-505. PubMed ID: 30958743
[TBL] [Abstract][Full Text] [Related]
10. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
11. T2-weighted imaging-based deep-learning method for noninvasive prostate cancer detection and Gleason grade prediction: a multicenter study.
Jin L; Yu Z; Gao F; Li M
Insights Imaging; 2024 May; 15(1):111. PubMed ID: 38713377
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
13. Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
Roberto D; Selvarajah S; Park PC; Berman D; Venkateswaran V
Prostate; 2019 Nov; 79(15):1777-1788. PubMed ID: 31503357
[TBL] [Abstract][Full Text] [Related]
14. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
15. Differentiation among prostate cancer patients with Gleason score of 7 using histopathology whole-slide image and genomic data.
Ren J; Karagoz K; Gatza M; Foran DJ; Qi X
Proc SPIE Int Soc Opt Eng; 2018 Feb; 10579():. PubMed ID: 30662142
[TBL] [Abstract][Full Text] [Related]
16. Biological determinants of cancer progression in men with prostate cancer.
Stamey TA; McNeal JE; Yemoto CM; Sigal BM; Johnstone IM
JAMA; 1999 Apr; 281(15):1395-400. PubMed ID: 10217055
[TBL] [Abstract][Full Text] [Related]
17. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
[TBL] [Abstract][Full Text] [Related]
18. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
20. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
